<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495454</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_GAEL</org_study_id>
    <secondary_id>2014-005697-10</secondary_id>
    <nct_id>NCT02495454</nct_id>
  </id_info>
  <brief_title>GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma</brief_title>
  <acronym>FIL_GAEL</acronym>
  <official_title>GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma A Phase II Study of the Fondazione Italiana Linfomi (FIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GA101-miniCHOP regimen for the treatment of elderly unfit patients with diffuse large B-cell
      non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Considering that the treatment of elderly unfit patients with DLBCL cannot be based on a full
      course of R-CHOP, and that using a less intense R-miniCHOP combination an acceptable cure
      rate can be achieved this study is designed to try to improve the cure rate in unfit patients
      with DLBCL byadopting the R-miniCHOP scheme substituting Rituximab with the more active GA101
      monoclonal antibody. The study hypothesis is that a higher activity of the treatment can be
      achieved without modifying the cytotoxic part of the treatment but using a more active
      immunotherapy. Differently from the previous experience with R-miniCHOP eligible patient are
      not only identified using anagraphic criteria but adopting CGA as part of initial assessment
      and considering as eligible unfit patients.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Primary objective not obtained after interim analysis
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Complete Response Rate after 10 infusions of GA101 and 6 cycles of miniCHOP. The response rate to therapy will be based a central Independent Review Committee of response that will not consider the results of FDG-PET but will only use the conventional CT scan images (International Criteria, B. Cheson, JCO 1999)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Rate of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRR</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Partial Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Overall Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from 60 months from first patient in</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from 60 months from first patient in</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living (ADL)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Change in ADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrumental Activities of Daily Living (IADL)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Change in IADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Illness Rating Scale (CIRS)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Change in CIRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire for quality of life (EORTC QLQ C30)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Change in quality of life (QoL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>CD20 Positive Diffuse Large B-cell Lymphoma</condition>
  <condition>Elderly Unfit Patients</condition>
  <arm_group>
    <arm_group_label>Ga101-miniCHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).
GA101-miniCHOP regimen:
Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os
Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os
Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ga101</intervention_name>
    <arm_group_label>Ga101-miniCHOP</arm_group_label>
    <other_name>Obinutuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven CD20 positive Diffuse Large B-cell Lymphoma and Follicular grade
             IIIB lymphoma, according to WHO classification (local pathologist)

          2. Age ≥ 65 years

          3. No previous treatment

          4. CGA assessment performed before starting treatment

          5. UNFIT patients defined as follows:

             Age &gt; 80 years with FIT profile, i.e. ADL =6 residual functions IADL=8 residual
             functions CIRS: no comorbidity of grade 3-4 and &lt;5 of grade 2 or Age &lt; 80 with UNFIT
             profile, i.e ADL &gt; 5 residual functions IADL &gt; 6 residual functions CIRS: no
             comorbidity of grade 3-4 and 5-8 co-morbidities of grade 2

          6. Ann Arbor Stage I with bulky, II-IV

          7. At least one bi-dimensionally measurable lesion defined as &gt; 1.5 cm in its largest
             dimension on CT scan

          8. ECOG performance status of 0, 1, or 2

          9. Adequate hematologic function (unless caused by bone marrow infiltrate), defined as
             follows:

             Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x
             109/L

         10. LVEF &gt;50%

         11. Ability and willingness to comply with the study protocol procedure

         12. Life expectancy &gt; 6 months

         13. Accessibility of patient for treatment and follow up

         14. Written informed consent

        Exclusion Criteria:

          1. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies or known sensitivity or allergy to murine products

          2. Contraindication to any of the individual components of CHOP, including prior receipt
             of anthracyclines

          3. History of other malignancies within 5 years prior to study entry except for
             adequately treated carcinoma in situ of the cervix or basal or squamous cell skin
             cancer

          4. Stage I without bulky

          5. Patients with transformed lymphoma

          6. Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation

          7. Previous exposure to cytotoxic agents

          8. Suspect or clinical evidence of CNS involvement by lymphoma

          9. HBsAg, HCV or HIV positivity; isolated HBcAb positivity is accepted only with
             concomitant treatment with Lamivudine

         10. AST /ALT &gt; twice upper the normal range; bilirubin &gt; twice upper the normal range;
             serum creatinine &gt; 2.5 mg /dl (unless these abnormalities were related to the
             lymphoma)

         11. Evidence of any severe active acute or chronic infection

         12. Concurrent co-morbid medical condition which might exclude administration of full dose
             chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Merli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ematologia - IRCCS Arcispedale Santa Maria Nuova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asmn-Irccs</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>43123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia 1U - AO Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria di Terni</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Degli Infermi</name>
      <address>
        <city>Biella</city>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Area Vasta Romagna e IRST</name>
      <address>
        <city>Meldola (FC)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDU Ematologia - Università del Piemonte Orientale</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia e TMO Dopartimento Oncologia La Maddalena</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl Di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl Di Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47924</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia - A.O. Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

